Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Terminated Phase 2Phase 3 Interventional Results available

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

NCT04695977
View directory record Official record
Conditions
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions
CMP-001, Nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Technological Advances in Glucose Management in Older Adults

NCT03078491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Older Adults, Hypoglycemia
Interventions
eCGM (enhanced CGM)
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
65 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 8:45 AM EDT
Active, not recruiting Phase 4 Interventional Results available

IO Vancomycin in TSA

NCT05831774
View directory record Official record
Conditions
Shoulder Injuries
Interventions
Intervention - Intraosseous (IO) administration of vancomycin, Control - Standard IV administration of vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 26, 2026, 8:45 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT07625280
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Xywav, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

NCT00491556
View directory record Official record
Conditions
HIV Infections
Interventions
Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 26, 2026, 8:45 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

NCT03520959
View directory record Official record
Conditions
Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma, Metastatic Sarcoma
Interventions
LV305, G305, LV305-matching placebo, G305-matching placebo
Biological · Other
Lead sponsor
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

NCT00823680
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO5027838, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
35 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 26, 2026, 8:45 AM EDT
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Reducing the Weight of Overweight Schizophrenia Patients

NCT00158366
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Behavioral training, Social skills training, Behavioral training booster sessions
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 60 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

NCT00152386
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CDP870)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 26, 2026, 8:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Application of the ICE-T Postoperative Multimodal Pain Regimen to Laparoscopic Hysterectomy

NCT04137770
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Ice pack and ketorolac
Other
Lead sponsor
Mercy Research
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 26, 2026, 8:45 AM EDT
Active, not recruiting Not applicable Interventional

Impact of Chewing Gum on Bowel Preparation in Patients Undergoing Colonoscopy

NCT07320989
View directory record Official record
Conditions
Colon Cancer Screening
Interventions
Chewing Sugar-Free Gum During Bowel Preparation, Standard Bowel Prep (2L PEG-ELP), Standard Bowel Prep
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 1Phase 2 Interventional

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

NCT04431258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABTL0812, Folfirinox, Placebo
Drug
Lead sponsor
Ability Pharmaceuticals SL
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

NCT01467726
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Velusetrag, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
65 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Managing Medication-induced Constipation in Cancer: A Clinical Trial

NCT01416909
View directory record Official record
Conditions
Constipation
Interventions
Laxative Treatment, Standard of Care, Assessment Questionnaires
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

NCT04001517
View directory record Official record
Conditions
Dementia With Lewy Bodies (DLB)
Interventions
Neflamapimod
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 2 Interventional

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Placebo, Indoximod, Paclitaxel
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

NCT00219063
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

NCT04740931
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 26, 2026, 8:45 AM EDT
Not yet recruiting Phase 4 Interventional

Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction

NCT07605923
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Methyl Prednisolone (MP), Standard Post-Operative Pain Control, Surgeon's Standard ACL Postoperative Regimen
Drug · Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 26, 2026, 8:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder

NCT01369459
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions
MIP Protocol
Behavioral
Lead sponsor
The National Center on Addiction and Substance Abuse at Columbia University
Other
Eligibility
13 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 26, 2026, 8:45 AM EDT